These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 9821967

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F, Jia S, Xing G, Gao L, Zhang L, He F.
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [Abstract] [Full Text] [Related]

  • 3. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H.
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [Abstract] [Full Text] [Related]

  • 4. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
    Luparello C, Del Rosso M.
    Eur J Cancer; 1996 Apr; 32A(4):702-7. PubMed ID: 8695276
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
    Sato S, Kopitz C, Schmalix WA, Muehlenweg B, Kessler H, Schmitt M, Krüger A, Magdolen V.
    FEBS Lett; 2002 Sep 25; 528(1-3):212-6. PubMed ID: 12297307
    [Abstract] [Full Text] [Related]

  • 7. Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis.
    Shetty S, Kumar A, Johnson A, Pueblitz S, Idell S.
    Am J Physiol; 1995 Jun 25; 268(6 Pt 1):L972-82. PubMed ID: 7611439
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V, Rettenberger P, Koppitz M, Goretzki L, Kessler H, Weidle UH, König B, Graeff H, Schmitt M, Wilhelm O.
    Eur J Biochem; 1996 May 01; 237(3):743-51. PubMed ID: 8647121
    [Abstract] [Full Text] [Related]

  • 10. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
    Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F.
    EMBO J; 1996 Apr 01; 15(7):1572-82. PubMed ID: 8612581
    [Abstract] [Full Text] [Related]

  • 11. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
    Guthaus E, Bürgle M, Schmiedeberg N, Hocke S, Eickler A, Kramer MD, Sweep CG, Magdolen V, Kessler H, Schmitt M.
    Biol Chem; 2002 Jan 01; 383(1):207-16. PubMed ID: 11930939
    [Abstract] [Full Text] [Related]

  • 12. Urokinase-type plasminogen activator induces proliferation in breast cancer cells.
    Gandhari M, Arens N, Majety M, Dorn-Beineke A, Hildenbrand R.
    Int J Oncol; 2006 Jun 01; 28(6):1463-70. PubMed ID: 16685447
    [Abstract] [Full Text] [Related]

  • 13. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
    Rettenberger P, Wilhelm O, Oi H, Weidle UH, Goretzki L, Koppitz M, Lottspeich F, König B, Pessara U, Kramer MD.
    Biol Chem Hoppe Seyler; 1995 Oct 01; 376(10):587-94. PubMed ID: 8590627
    [Abstract] [Full Text] [Related]

  • 14. Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase.
    Liu J, Chakraborty C, Graham CH, Barbin YP, Dixon SJ, Lala PK.
    Exp Cell Res; 2003 May 15; 286(1):138-51. PubMed ID: 12729802
    [Abstract] [Full Text] [Related]

  • 15. Urokinase-type plasminogen activator induces tyrosine phosphorylation of a 78-kDa protein in H-157 cells.
    Bhat GJ, Gunaje JJ, Idell S.
    Am J Physiol; 1999 Aug 15; 277(2):L301-9. PubMed ID: 10444524
    [Abstract] [Full Text] [Related]

  • 16. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H, Soria C, Griscelli F, Opolon P, Soria J, Yeh P, Legrand C, Vannier JP, Belin D, Perricaudet M, Lu H.
    Hum Gene Ther; 2005 Oct 15; 16(10):1157-67. PubMed ID: 16218777
    [Abstract] [Full Text] [Related]

  • 17. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C, Yu J, Huang S.
    Mol Carcinog; 2007 Mar 15; 46(3):165-75. PubMed ID: 17186542
    [Abstract] [Full Text] [Related]

  • 18. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ, Lee SW, Dichek DA, Ellis V.
    J Pept Sci; 2000 Sep 15; 6(9):432-9. PubMed ID: 11016879
    [Abstract] [Full Text] [Related]

  • 19. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
    Stepanova V, Mukhina S, Köhler E, Resink TJ, Erne P, Tkachuk VA.
    Mol Cell Biochem; 1999 May 15; 195(1-2):199-206. PubMed ID: 10395084
    [Abstract] [Full Text] [Related]

  • 20. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
    Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J, Goltzman D.
    J Biol Chem; 1992 Jul 15; 267(20):14151-6. PubMed ID: 1321137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.